Advertisement

Topics

Norwegian Biotech Lands a Blow in the Fight Against Pancreatic Cancer

07:47 EDT 12 Oct 2017 | Labiotech.eu

A Phase I/II trial investigating Targovax’s pancreatic cancer candidate, TG01, saw it keep 100% of trial participants alive 1 year post-surgery. Targovax develops immuno-oncology therapies targeting solid tumors. The company’s candidate, TG01, is under development to treat pancreatic cancer, one ...

This awesome article Norwegian Biotech Lands a Blow in the Fight Against Pancreatic Cancer appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Norwegian Biotech Lands a Blow in the Fight Against Pancreatic Cancer

NEXT ARTICLE

More From BioPortfolio on "Norwegian Biotech Lands a Blow in the Fight Against Pancreatic Cancer"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...